NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Down 2.4 %

NURO opened at $3.59 on Tuesday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The business’s 50 day moving average is $4.03 and its two-hundred day moving average is $3.86.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the firm earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.